New Pharmacovigilance Team Established

BMI View: Improving the regulatory pharmaceutical business environment will continue to attract foreign direct investment (FDI) into the UAE, despite its relatively lower levels of drug spending compared with Saudi Arabia. A lack of regulatory polices is a significant drawback to many emerging markets and we believe the UAE is a prime example of how continuous efforts to attract foreign business can overcome limiting barriers to market values, including low domestic demand.

To read the full article, please choose one of the following options: